CD&R initially invested in Cynosure in December 2019, facilitating the carve out of the company from Hologic.

Cynosure, LLC, received $60 million from lead investor Clayton, Dubilier & Rice. 

The new capital supports the company's plans to continue investing ahead of strong growth to bring innovation to the market and provide comprehensive treatment solutions to its customers that deliver the highest clinical efficacy for patients.

Cynosure saw sales grow by over 45 percent in 2021 and over 30 percent year-over-year in the first quarter of 2022, driven by strong growth across all geographies.

"We are pleased that CD&R continues to share our excitement about Cynosure's market, growth trajectory, and potential to accelerate," saysTodd Tillemans, Cynosure CEO, in a news release.  "This investment is a strong endorsement that Cynosure is delivering on its mission to be the leader in aesthetics and to help patients across the globe to unleash their beautiful energy from within."

"We have built at Cynosure a diverse and talented team, and I believe the company's strong sales performance is the direct result of the team's exceptional execution against high demand in the market," adds Sandi Peterson, CD&R Partner and Chairman of Cynosure's Board of Directors. "We are excited to continue our partnership with the team to support their efforts to drive continued new and future breakthrough product innovation and deliver the best service and solutions to Cynosure's valued customers."

"Medical aesthetics is a large market with strong macro tailwinds that have only gotten stronger across the globe since our initial investment," says Derek Strum, CD&R Partner. "We believe Cynosure is well positioned to build on its momentum and capture both organic and inorganic growth opportunities."

CD&R initially invested in Cynosure in December 2019, facilitating the carve out of the company from Hologic.